InflaRx’s (IFRX) Buy Rating Reiterated at HC Wainwright

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $8.00 target price on the stock.

InflaRx Price Performance

Shares of IFRX stock traded down $0.01 during trading hours on Friday, hitting $1.21. The stock had a trading volume of 260,855 shares, compared to its average volume of 210,844. The stock has a market capitalization of $80.90 million, a price-to-earnings ratio of -1.11 and a beta of 1.98. The stock’s 50-day moving average price is $2.19 and its two-hundred day moving average price is $1.92. InflaRx has a one year low of $1.17 and a one year high of $2.82.

Hedge Funds Weigh In On InflaRx

A number of large investors have recently made changes to their positions in IFRX. Raymond James Financial Inc. purchased a new position in shares of InflaRx in the fourth quarter valued at approximately $1,576,000. Commonwealth Equity Services LLC grew its holdings in shares of InflaRx by 20.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after buying an additional 19,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of InflaRx by 32.8% in the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after purchasing an additional 11,900 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of InflaRx in the fourth quarter valued at approximately $51,000. Finally, Two Sigma Securities LLC purchased a new stake in shares of InflaRx in the fourth quarter valued at $28,000. 42.39% of the stock is owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.